+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 17 Actively Recruiting clinical trials

P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating DB-2304 in a Phase 12a study involving healthy adults and individuals with Systemic Lupus Erythematosus SLE or Cutaneous Lupus Erythematosus CLE. The study aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of DB-2304 for injection in these participants. This trial is randomized and double-blind, sponsored by DualityBio Inc., and includes adults aged 18 to 70 years. Participants receive different dose levels of DB-2304 or placebo, with some also receiving prednisone as part of their stable treatment regimen. The study includes two parts Part A with healthy adults aged 18 to 55, and Part B with adults aged 18 to 70 having SLE or CLE. Treatments are administered by injection, and participants are randomly assigned to one of several dose levels to evaluate different dosing effects. During the study, participants will undergo monitoring for treatment-emergent adverse events, serious adverse events, and various vital signs including ECG, heart rate, respiratory rate, body temperature, and weight. These measurements are tracked for up to 112 days after treatment in Part A and up to 280 days after the first treatment in Part B. The study involves regular assessments to evaluate safety and treatment response over these periods.

Age: 18Years - 70YearsAll GendersPhase 1Phase 2
7 locations
S

Actively Recruiting

This research aims to describe the characteristics of people with asthma, covering a wide range of disease severities. It studies sociodemographic and clinical features, treatment patterns, disease burden, biomarkers, and health-related quality of life. The study includes both a cross-sectional part and a prospective follow-up to observe changes in asthma over time. Participants are grouped based on their asthma treatments and disease control, including those receiving various doses of inhaled corticosteroids or biologic therapies as part of their usual care. The study has two main parts Part 1 assesses characteristics at baseline, while Part 2 follows participants for two years to evaluate changes in symptoms, lung function, treatment use, and biomarkers. During the study, participants will provide information through questionnaires and clinical assessments, including lung tests and blood samples. Researchers will collect both participant- and physician-reported outcomes to analyze asthma severity, control, quality of life, and healthcare use. The study extends up to two years, with evaluations at baseline and at weeks 52 and 104 to understand disease progression and treatment patterns.

Age: 6Years +All Genders
71 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
O

Actively Recruiting

Researchers are studying participants with active systemic lupus erythematosus SLE, including those with lupus nephritis, who have not responded adequately to glucocorticoids and at least two immunosuppressant therapies. The aim is to characterize the effectiveness and safety of current standard of care treatments for this condition. This observational study focuses on understanding how these treatments work in real-world settings for patients with active disease. Participants receive treatments based on the current standard of care according to product guidelines, including biologic therapies among other immunosuppressants. The study specifically includes those with active disease confirmed by clinical assessments and positive autoantibodies. Participants with lupus nephritis must have had a recent renal biopsy showing specific active kidney involvement. Treatment and observation continue over several years to evaluate long-term outcomes. During the study, participants undergo evaluations at regular intervals up to 60 months. Researchers assess disease remission, kidney function, disease activity scores, flare frequency, and patient-reported fatigue. Data collection involves clinical assessments, laboratory tests, and questionnaires to measure treatment response and safety. This long-term follow-up provides insight into how well patients maintain remission and respond to standard therapies over time.

Age: 16Years +All Genders
70 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of nipocalimab compared to placebo in adults with moderate to severe systemic lupus erythematosus SLE, a long-term autoimmune disease where the immune system attacks healthy tissues causing inflammation in various organs. This phase 3, randomized, double-blind study aims to determine how well nipocalimab works alongside standard care treatments in managing SLE symptoms and disease activity. Participants will receive either nipocalimab or placebo combined with standard care treatments during a 52-week double-blind period. After this, eligible participants from both groups can join an open-label extension where they will continue to receive nipocalimab until Week 156 or until the study intervention is stopped. This design allows comparison of nipocalimabs effects versus placebo and longer-term safety and effectiveness in an open-label setting. Throughout the study, participants undergo regular assessments including disease activity indexes, joint evaluations, and fatigue scores. Researchers will track the percentage of participants achieving a standard SLE response measure at Week 52 and monitor changes in oral glucocorticoid use, joint pain, and flare-free status. Safety and treatment adherence are closely monitored across study visits, with data collected up to 3 years for long-term evaluation.

Age: 18Years - 75YearsAll GendersPhase 3
272 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating an investigational mRNA seasonal flu vaccine compared to a licensed flu vaccine in adults aged 65 years and older. The study aims to assess the ability of the vaccines to prevent laboratory-confirmed influenza illness, monitor side effects, and measure immune responses during the flu season. This Phase 3 randomized, observer-blind trial is sponsored by GlaxoSmithKline and focuses on flu prevention in older adults. Participants will receive a single injection on Day 1 of either the investigational mRNA seasonal flu vaccine or a licensed, age-appropriate, season-adapted influenza vaccine. The study follows a parallel group design where participants are randomly assigned to one of these two vaccine groups. The follow-up period covers the entire influenza season to assess vaccine efficacy and safety. During the study, participants will be monitored for influenza-like illness confirmed by laboratory tests from Day 15 through the end of the influenza season. Safety assessments include tracking solicited local and systemic side effects from Day 1 to Day 7, unsolicited adverse events up to Day 28, and serious adverse events or special interest adverse events through at least 180 days of follow-up. Blood samples will be collected before dosing and on Day 29 to evaluate immune responses. Participants are followed for safety and efficacy throughout the flu season, with total involvement spanning several months.

Age: 65Years +All GendersPhase 3
163 locations
A

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a new drug called GSK3862995B in adults with bronchiectasis, a chronic lung disease. This Phase 2 study also examines how the body processes the drug and checks for any immune reactions. Participants will be randomly assigned to receive one of two doses of GSK3862995B or a placebo to compare their effects on bronchiectasis. Participants will receive either Dose Level 1 or Dose Level 2 of GSK3862995B, or a matching placebo. The study uses a double-blind, randomized design, meaning neither participants nor researchers know who gets which treatment. The treatment period lasts up to 48 weeks, during which participants receive repeated doses. The study also includes assessments up to 72 weeks to monitor safety and immune responses. During the trial, participants will undergo evaluations including lung function tests, quality-of-life questionnaires, and monitoring of respiratory symptoms. Researchers will track the number of lung exacerbations, serious adverse events, laboratory tests, vital signs, and electrocardiograms to assess safety and effectiveness. Participants will be involved in regular visits and assessments throughout the treatment and follow-up periods, lasting up to about 72 weeks in total.

Age: 18Years - 85YearsAll GendersPhase 2
134 locations
E

Actively Recruiting

Researchers are evaluating dapirolizumab pegol DZP as an additional treatment alongside standard care medications for people with moderately to severely active systemic lupus erythematosus SLE. The study aims to determine if DZP can provide meaningful long-term improvement in disease activity compared to placebo. This is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by UCB Biopharma SRL. Participants are randomly assigned to receive either dapirolizumab pegol or a placebo throughout the treatment period. Both groups continue their standard of care medication during the trial. The treatment is administered at prespecified time points during the study, which lasts for 48 weeks. The study monitors disease activity and safety outcomes during this time. During the study, participants will attend regular visits to assess disease activity using measures such as the British Isles Lupus Assessment Group Disease Activity Index BILAG 2004 and the Systemic Lupus Erythematosus Disease Activity Index 2000 SLEDAI-2K. Researchers will also evaluate fatigue, glucocorticoid dose reduction, and record any treatment-emergent adverse events. Safety follow-up continues up to 54 weeks. Overall participation lasts nearly a year, including treatment and follow-up assessments.

Age: 16Years +All GendersPhase 3
245 locations
O

Actively Recruiting

Researchers are studying the effects of anifrolumab, given as a 120 mg subcutaneous injection once weekly, for patients with systemic lupus erythematosus SLE who have not used immunosuppressants or biologic therapies before. The study aims to understand clinical outcomes like remission rates and the ability to taper off glucocorticoids GCs safely in patients not meeting low disease activity status at enrollment. Participants will receive anifrolumab injections weekly for 52 weeks, alongside their usual antimalarial treatment, with or without glucocorticoids. The study includes a 35-day screening period before treatment starts. Glucocorticoid doses may be increased during the first 4 weeks if needed, then tapered gradually between weeks 5 and 40 following a specific protocol. Those achieving remission can attempt complete withdrawal of glucocorticoids after tapering. After week 41, glucocorticoid doses will remain stable. Safety follow-up occurs 12 weeks after the last dose for participants who stop treatment after week 52. Participants will undergo regular assessments throughout the study to evaluate disease activity, remission status, glucocorticoid use, and quality of life. Researchers will monitor various outcomes, including time spent in remission, flare occurrences, skin and joint symptoms, and adverse events. The total participation time is approximately 69 weeks, including screening, treatment, and safety follow-up, with detailed tracking of glucocorticoid use and disease status at multiple time points.

Age: 18Years - 70YearsAll GendersPhase 3
107 locations
S

Actively Recruiting

Researchers are evaluating the efficacy, safety, tolerability, immune response, and how the body processes PRX-115, a recombinant pegylated Uricase, in adults with gout who have difficulty lowering their serum uric acid levels with standard treatments. This phase II, randomized, double-blind, placebo-controlled study also examines the effects of combining PRX-115 with methotrexate MTX, an immunomodulator, compared to placebos. The trial aims to find the best dosing schedule for intravenous PRX-115 infusions over 24 weeks. Participants are randomly assigned to receive PRX-115 infusions intravenously on different schedules every 4 weeks for six doses, every 6 weeks for four doses, or every 8 weeks for three doses. Some groups receive PRX-115 with oral MTX at 15 mg weekly, while others receive PRX-115 with a placebo MTX or placebo infusions with placebo MTX. This parallel design allows comparison of different dosing regimens with and without MTX. The treatment period lasts 24 weeks with multiple infusions according to the assigned schedule. During the study, participants undergo regular monitoring including blood tests to measure serum uric acid levels and safety assessments. Researchers track the percentage of participants achieving serum uric acid below 6 mgdL at six months as the primary outcome, along with other time-point measurements and treatment-emergent side effects. The study includes up to 8 months of follow-up to assess safety and tolerability. Participants health status, immunogenicity, pharmacokinetics, and pharmacodynamics of PRX-115 are also evaluated throughout the trial.

Age: 18Years +All GendersPhase 2
35 locations

1-10 of 17

1